Also known as CoVLP, Covifenz
~6 min read
CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi, who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.
It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).